4//SEC Filing
Margrave David R. 4
Accession 0001493152-25-014612
CIK 0001763950other
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 4:05 PM ET
Size
12.8 KB
Accession
0001493152-25-014612
Insider Transaction Report
Form 4
Margrave David R.
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-10-29+26,100→ 26,100 totalExercise: $5.04Exp: 2031-10-28→ Common Stock (26,100 underlying) - Award
Stock Option (Right to Buy)
2020-06-15+78,300→ 78,300 totalExercise: $5.04Exp: 2030-06-14→ Common Stock (78,300 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-15−78,300→ 0 totalExercise: $15.00Exp: 2030-06-14→ Common Stock (78,300 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-10-29−26,100→ 0 totalExercise: $10.21Exp: 2031-10-28→ Common Stock (26,100 underlying)
Footnotes (2)
- [F1]The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date).
- [F2]The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021.
Documents
Issuer
Lantern Pharma Inc.
CIK 0001763950
Entity typeother
Related Parties
1- filerCIK 0001813162
Filing Metadata
- Form type
- 4
- Filed
- Sep 22, 8:00 PM ET
- Accepted
- Sep 23, 4:05 PM ET
- Size
- 12.8 KB